Medicine and Dentistry
Prostate Cancer
100%
Castration Resistant Prostate Cancer
43%
Neoplasm
36%
Malignant Neoplasm
33%
Biological Marker
31%
Diseases
29%
Enzalutamide
23%
Androgen Deprivation Therapy
17%
Transitional Cell Carcinoma
17%
Adenocarcinoma
17%
Antibody-Drug Conjugate
17%
Circulating Tumor Cell
16%
Magnetic Resonance Imaging
15%
Targeted Therapy
15%
Olaparib
15%
Androgen Receptor
13%
Prostatectomy
12%
Biopsy Technique
9%
Metastatic Carcinoma
9%
Clinician
9%
Treatment Response
9%
Prostate Tumor
9%
Pembrolizumab
9%
Immunotherapy
9%
PARP Inhibitor
8%
Multiparametric Magnetic Resonance Imaging
8%
Prostate Tissue
7%
Morphology
7%
Antiandrogen
7%
Durvalumab
7%
Veliparib
7%
Drug Sensitivity
7%
Cytotoxic Chemotherapy
7%
Hormone Therapy
7%
PI3K/AKT Pathway
7%
Phosphatase
7%
Disease Course
7%
Robot-Assisted Prostatectomy
7%
Tensin
7%
Prednisolone
7%
Leukemia Cell
7%
BRCA2
7%
DNA Repair
7%
Receptor Protein
7%
Acute Lymphoblastic Leukemia
7%
Human Serum Albumin
7%
Protein Expression
7%
Glucocorticoid Receptor
7%
Osimertinib
7%
Epidermal Growth Factor Receptor
7%
Keyphrases
Prostate Cancer
88%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
44%
Tumor
26%
Multiparametric MRI (mpMRI)
23%
Advanced Prostate Cancer
23%
Predictive Biomarker
22%
Androgen Deprivation Therapy
20%
High-grade Prostate Cancer
17%
Antibody-drug Conjugate
17%
Enzalutamide
16%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
16%
PARP Inhibitor (PARPi)
16%
Saccharomyces Cerevisiae
15%
Olaparib
15%
Circulating Tumor Cells
15%
Mammalian Target of Rapamycin (mTOR)
15%
Pancreatic Adenocarcinoma
13%
Ductal Adenocarcinoma
13%
Targeted Therapy
13%
Mammalian Cells
12%
Bcl-xL
12%
Complete Response
11%
Durable Response
11%
Nave
11%
In Cancer
10%
Prostate Tumor
10%
Glycolytic Rate
10%
Cancer Immunotherapy
10%
Treatment Decisions
9%
Pembrolizumab
9%
Adenocarcinoma
9%
Androgen Receptor
9%
Neoadjuvant
8%
Localized Prostate Cancer
8%
Patient-specific
8%
Clinical Trials
8%
Prostatectomy
7%
Gleason
7%
Cancer Genome
7%
National Cancer Institute
7%
PI3K-Akt Pathway
7%
Population-based
7%
Unmet Medical Need
7%
Smart Nanocarriers
7%
Metastatic Disease
7%
Treatment Paradigms
7%
Disease Heterogeneity
7%
Advanced Urothelial Carcinoma
7%
Actionable Target
7%
Durvalumab
7%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
59%
Castration Resistant Prostate Cancer
40%
Neoplasm
36%
Malignant Neoplasm
33%
Diseases
23%
Biological Marker
22%
Immunotherapy
16%
Olaparib
15%
Antibody Drug Conjugate
15%
Enzalutamide
14%
Androgen Receptor
13%
Protein Kinase B
11%
Androgen
9%
Adenocarcinoma
9%
Prostate Tumor
9%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
8%
Saccharomyces cerevisiae
7%
Durvalumab
7%
Nanocarrier
7%
Receptor Protein
7%
Cisplatin
7%
Cytotoxic Chemotherapy
7%
Reactive Oxygen Metabolite
7%
Nucleic Acid
7%
Veliparib
7%
Human Serum Albumin
7%
Glutathione
7%
Disease Course
7%
Glucocorticoid Receptor
7%
Mammalian Target of Rapamycin
7%
Transitional Cell Carcinoma
7%
Pembrolizumab
7%
Membrane Cofactor Protein
7%
Human Study
7%
Prostate Specific Antigen
7%
Abiraterone
6%
Progression Free Survival
6%
Gleason Score
6%
Poly(adenosine Diphosphate Ribose)
5%
Clinical Trial
5%